Improving outcomes with long-term “destination” therapy using left ventricular assist devices  James W. Long, MD, PhD, Aaron H. Healy, BS, Brad Y. Rasmusson, MD, Cris G. Cowley, MD, Karl E. Nelson, RN, MBA, Abdallah G. Kfoury, MD, Stephen E. Clayson, MD, Bruce B. Reid, MD, Stephanie A. Moore, MD, Douglas U. Blank, MD, Dale G. Renlund, MD  The Journal of Thoracic and Cardiovascular Surgery  Volume 135, Issue 6, Pages 1353-1361 (June 2008) DOI: 10.1016/j.jtcvs.2006.09.124 Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 LDSH DT versus REMATCH LVAD. One year post-implant: REMATCH, 52% ± 6%; LDS DT, 77% ± 10%; P = .0355. Two years post-implant: REMATCH, 29% ± 6%; LDS DT, 77% ± 10%; P < .0001. LDSH, LDS Hospital; LVAD, left ventricular assist device. The Journal of Thoracic and Cardiovascular Surgery 2008 135, 1353-1361DOI: (10.1016/j.jtcvs.2006.09.124) Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions